This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pruneri, G. Articles by Viale, G. Search for Related Content PubMed PubMed Citation Articles by Pruneri, G. Articles by Viale, G.

Cyclin D3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma

Divisions of ¹ Pathology and Laboratory Medicine, ² Epidemiology and Biostatistics, and ³ Experimental Oncology, European Institute of Oncology and University of Milan School of Medicine, ⁴ Otorhinolaryngology Clinic, ⁵ Laboratory of Experimental Hematology and Molecular Genetics, and ⁶ Anaesthesiology and Intensive Care, Ospedale Maggiore, Istituto di Ricovero e Cura a Carattere Scientifico, and ⁷ FIRC Institute of Molecular Oncology, Milan, Italy

Requests for reprints: Giancarlo Pruneri, Division of Pathology and Laboratory Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. Phone: 39-025-748-9412; Fax: 39-025-748-9417; E-mail: giancarlo.pruneri{at}ieo.it.

Purpose: To analyze the prevalence and clinical relevance of cyclin D3 abnormalities in laryngeal squamous cell carcinoma (LSCC).

Experimental Design: Cyclin D3 immunoreactivity was evaluated in 223 formalin-fixed and paraffin-embedded samples of LSCC patients with a mean follow-up of 62.8 ± 43.2 months. The occurrence of cyclin D3 extra signals was analyzed by fluorescence in situ hybridization in 47 randomly selected cases collected in a tissue microarray. Cyclin D1 immunoreactivity had been previously investigated in 133 cases.

Results: Cyclin D3 immunoreactivity and gene extra signals were found in 39.5% and 42.6% of the cases, respectively, and the concordance between immunohistochemical and fluorescence in situ hybridization results was 70.2% (P = 0.0085). Cyclin D3 immunoreactivity was significantly associated with a high risk of death. Multivariate analysis showed that high tumor grade, exophytic/ulcerating tumor type, low performance status, and cyclin D3 immunoreactivity were the only independent predictors of poor overall survival. In the 133 cases analyzed for both cyclin D1 and cyclin D3, patients with cyclin D1⁺/cyclin D3⁺ tumors experienced the worst prognosis, patients with cyclin D1^–/cyclin D3^– exhibited the most prolonged survival, and with cyclin D1^–/cyclin D3⁺ or cyclin D1⁺/cyclin D3^– tumors an intermediate course was associated.

Conclusions: Our data suggest that cyclin D3 immunoreactivity, possibly due to the occurrence of gene extra copies, may represent an adjunct in LSCC patients' prognostication and contribute to identify D-type cyclins as potential targets of newly developed therapies.

This article has been cited by other articles:

				G Troncone, A Iaccarino, M Russo, E A Palmieri, M Volante, M Papotti, G Viglietto, and L Palombini Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma J. Clin. Pathol., April 1, 2007; 60(4): 377 - 381. [Abstract] [Full Text] [PDF]